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Paclitaxel Drug-coated Balloon For The Treatment Of Drug-eluting Stent In-stent
Restenosis: Subanalysis Results Of The Valentines I Trial
Joshua P Loh,1 Pieter R Stella,2 Giuseppe Sangiorgi,3 Sigmund Silber,4
Stefanic Stahnke,5 Rembert Pogge von Strandmann,5 Zhenyi Xue,1 Rebecca Torguson,1
Ron Waksman1
1MedStar Washington Hospital Center, Washington, DC; 2University Medical Center
Utrecht, Utrecht, Netherlands 3University of Rome, Rome, Italy 4Heart Center at the
Isar, Munich, Germany 5Eurocor GmbH, Bonn, Germany MedStar Washington
Background: In the Valentines I trial, treatment of coronary in-stent restenosis was
effective and safe with the second-generation DIOR® paclitaxel drug-coated balloon
(DCB). We analyzed the effect of DCB treatment on patients with drug-eluting stent
(DES) restenosis.
Methods: Valentines I trial prospectively enrolled 250 patients with ISR. Of these, 74
patients (29.6%) had DES restenosis. Patients underwent balloon angioplasty followed by
DCB treatment. Clinical outcomes of patients with paclitaxel DES restenosis (34 patients
with 41 lesions) and -limus (sirolimus, everolimus and zotarolimus) DES restenosis (42
patients with 43 lesions) treated with DIOR® DCB were compared.
Results: Baseline characteristics were similar in both groups. There were more diffuse
pattern of restenosis in paclitaxel DES compared to -limus DES restenosis (50% vs.
26.8%, p0.032). Number of DCB used per patient (1.07 each group), mean DCB
diameter (2.95mm vs. 3.02mm), mean DCB length (26.7mm vs. 22.5mm) and bailout
stenting (2.6% vs. 4.7%) were similar in both groups (pNS). At mean follow-up of
231 43 days, major adverse cardiac events was 0% in the paclitaxel DES restenosis and
23.8% in the -limus DES restenosis (p0.002), the difference contributed mainly by less
target vessel revascularization (0 vs. 18.6%, p0.006) (Table).
Conclusion: In the Valentines I trial, the use of paclitaxel DCB was more effective in
patients with paclitaxel DES restenosis compared to -limus DES restenosis, achieving
better mid-term clinical outcomes. This suggests the efficacy of localized paclitaxel delivery
to overcome paclitaxel resistance but not -limus resistance due to different mechanisms of
DES failure.










lesions, n43) P value
Major adverse cardiac
events
0 10 (23.8%) 0.002
Death 0 1 (2.4%) 1.00
Myocardial infarction 0 1 (2.4%) 1.00
Vessel thrombosis 0 2 (4.8%) 0.50
Target lesion
revascularization
0 6 (14.0%) 0.027
Target vessel
revascularization
0 8 (18.6%) 0.006
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The State Of The Excimer Laser For Coronary Intervention In The Drug-eluting
Stent Era
Salem Badr, Itsik Ben-Dor, Israel Barbash, Sa’ar Minha, Hironori Kitabata,
Joshua Loh, Lakshmana Pendyala, Rebecca Torguson, Fang Chen, William Suddath,
Lowell Satler, Augusto Pichard, Ron Waksman
Medstar Washington Hospital Center, Washington, DC
Objectives: This study aimed to determine how Excimer laser coronary atherectomy
(ELCA) performs in the drug-eluting stent (DES) era.
Background: For more than 20 years, ELCA has been used for coronary intervention.
With developments in the coronary intervention field, the role of ELCA is in question.
Methods: The study includes 119 patients with 124 lesions who underwent percutaneous
coronary intervention (PCI) with ELCA in our institution from January 2004 to May 2011.
Results (Table): The main indications for ELCA use were saphenous vein graft (SVG)
(45 lesions), acute myocardial infarction (AMI) (7 lesions), chronic total occlusion (CTO)
(32 lesions), in-stent restenosis (ISR) (15 lesions), and calcified de-novo lesions (25
lesions). High success rates were recorded for the SVG, AMI, CTO, ISR, and calcified
lesion indications (91.1%, 85.7%, 93.8%, 86.7%, and 80%; respectively). ELCA related
complications were reported in 10 patients (8%); four dissections, three no-reflow
phenomenon, two perforations, and one thrombus formation.
Conclusion: ELCA is an alternative solution with an acceptable performance in the



















ELCA success® 41 (91.1%) 6 (85.7%) 30 (93.8%) 13 (86.7%) 20 (80%)
Angiographic
success¥
42 (93.3%) 7 (100%) 29 (90.6%) 14 (93.3%) 21 (84%)
Balloon non-crossable 2.0 (4.4%) 0 23 (71.9%) 2.0 (13.3%) 14 (56%)
Complications:
Dissection 0 0 3 (9.4%) 1 (6.7%) 0
Perforation 0 0 1 (3.1%) 0 1 (4.0%)
No-reﬂow 0 0 0 1 (6.7%) 2 (8.0%)
Thrombus formation 0 0 1 (3.1%) 0 0
®ELCA success was defined as the laser catheter crossing the entire length of the stenotic lesion
determined by angiographic evidence of the catheter tip in the artery distal to the stenosis. ¥Angio-
graphic successwas defined as50%residual stenosis after laser andadjunctive therapy
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Catheter-based Renal Denervation with the Symplicity™ System Provides Safe and
Durable Blood Pressure Reduction out to Three Years
David E Kandzari,1 Henry Krum2
1Piedmont Heart Institute, Atlanta, GA; 2Monash University/Alfred Hospital,
Melbourne, Australia
Background: The Symplicity™ renal denervation catheter uses low power radiofre-
quency energy to ablate the renal artery nerves and has been shown to lower blood pressure
(BP) in patients with treatment-resistant hypertension. Continued follow-up of patients
who have undergone renal denervation (RDN) is essential to establish the long-term
safety and effectiveness of this procedure.
Methods: The open-label Symplicity HTN-1 study enrolled 153 patients with severe
resistant hypertension (systolic BP 160 mm Hg in the presence of 3 antihypertensive







drugs, including a diuretic). A subset of patients (n129) is being followed to 3 years
post-RDN (35 consented to laboratory assessments to 3 years). The primary endpoint is
change in office-based BP from baseline. Data collection includes office-based BP
measurement every 6 months, renal function, electrolytes, and medication usage.
Results: A total of 34 patients have reached the 3 year follow-up time point (9 with labs).
Baseline BP was 175/9812/11 mmHg. Mean SBP change post-RDN was -18.016.6
mm Hg at 1 month, -28.4 17.6 mm Hg at 6 months, -27.6 16.3 mm Hg at 2 years
and -31.3 14.9 mm Hg at 3 years. Medication usage remained similar to baseline with
35% aldosterone antagonist, 85% beta blocker and 82% calcium channel blocker use at
baseline and at 3 years; diuretic use 91% and 88%, angiotensin receptor antagonists 71% and
76%, and ACE inhibitors 50% and 59% at baseline and 3 years, respectively. At 3 years
estimated glomerular filtration rates (eGFR) declined by -13.212.1 from a baseline of
82.216.1 mL/min/m2.
Conclusions: Among patients with full 3 year follow-up, RDN results in significant,
sustained lowering of SBP in patients with treatment-resistant hypertension and a baseline
SBP 160 mm Hg. Antihypertensive medication usage was similar at baseline and 3 years.
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Multi-center, First-in-man Evaluation Of The Myolimus-eluting Bioresorbable
Coronary Scaffold: 6-month Clinical And Imaging Results
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Aims: To evaluate the clinical safety and effectiveness of the DESolve™ Myolimus-
Eluting Bioresorbable Coronary Scaffold (BCSS)in patients with single de novo native
coronary artery lesions through clinical endpoints and multiple imaging modalities.
Methods and Results: Background: The DESolve BCSS is a novel drug eluting device
that combines a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor has
demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using
Elixir’s metallic Myolimus-eluting coronary stents. Drug dose is 3 mcg per mm of scaffold
length; the same dose used in the FIM studies. Sixteen patients with single, de novo
coronary artery lesions were enrolled in this prospective, multi-center, single-arm FIM
study. One patient did not receive a study stent and was deregistered. The 15 remaining
patients are being analysed for multiple clinical endpoints: Device and Procedure Success;
Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target
vessel MI, and clinically-indicated target lesion revascularization (CI-TLR); clinically-
indicated Target Lesion and Target Vessel Revascularization, (CI-TVR) and stent
thrombosis assessed at 1, 6 and 12 months and annually to 5 years. Multiple assessments
by angiographic, IVUS and OCT at 6 months were completed. An additional analysis
using multislice computed tomography (MSCT) will be completed at 12 and 24 months.
At 6 months, the in-scaffold late lumen loss was 0.19  0.19 by QCA, the % volume
obstruction was 7.18  3.37 by IVUS, and by OCT 98.68  2.44% of struts were
demonstrated as covered. There was one MACE event, a TLR, during the follow-up
period. Detailed clinical and imaging results through 12 months will be presented.
Conclusion: The DESolve™ Myolimus-Eluting BCSS demonstrated both excellent
safety and effectiveness in this FIM study, thus warranting further clinical evaluation of the
novel technology in larger clinical studies. Detailed clinical and imaging results through 12
months will be presented.
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Why Patients Presenting with Acute Myocardial Infarction Undergoing Primary
Percutaneous Coronary Intervention and Treated with Prasugrel are Switching Back
to Clopidogrel
Joshua P Loh, Lakshmana K Pendyala, Hironori Kitabata, Israel M Barbash,
Danny Dvir, Salem M Badr, Sa’ar Minha, Rebecca Torguson, Lowell F Satler,
Kenneth M Kent, William O Suddath, Augusto D Pichard, Ron Waksman
MedStar Washington Hospital Center, Washington, DC
Background: The reasons for switching from prasugrel back to clopidogrel after
percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are
unclear, but are frequently practiced. The study aims to compare the characteristics and
in-hospital outcomes of patients initially given prasugrel but was switched back to
clopidogrel versus those who were continued on prasugrel on discharge.
Methods: The study included a cohort of 152 consecutive AMI patients who were first
loaded with prasugrel and underwent PCI. Patients were categorized into switched
therapy to clopidogrel on discharge (Switched, n58) and continued therapy on prasugrel
on discharge (Continued, n94). Patient and procedural characteristics, as well as
PCI-related complications and in-hospital outcomes were evaluated.
Results: Baseline demographics and procedural characteristics of both groups were
similar. Patients who switched to clopidogrel on discharge had significantly longer
hospital stay, and intensive care unit stay trended longer. Switched patients had
significantly higher incidence of blood transfusions. Major bleeding, hematocrit drop,
hematoma and urgent coronary artery bypass grafting (CABG) also trended higher in
patients who switched therapy.
Concomitant coumadin therapy was significantly higher in the switched therapy group,
whereas aspirin therapy was similar in both groups. No in-hospital mortality or myocardial
infarction occurred in either groups (Table).
Conclusion: In-hospital bleeding complications requiring blood transfusion, need for
urgent CABG and concomitant coumadin therapy are the main reasons for switching of
antiplatelet therapy from prasugrel to clopidogrel prior to discharge.







Length of stay in intensive
care unit (days)
1.1 1.5 0.7 1.0 0.051
Overall hospital length of
stay (days)
4.3 4.3 2.9 1.8 0.021





3 (5.2%) 0 0.054
Blood transfusion 7 (12.1%) 0 0.001
Major bleeding 4 (6.9%) 1 (1.1%) 0.070
Hematocrit drop 15% 5 (8.5%) 1 (1.1%) 0.060
Hematoma 4 (6.9%) 1 (1.1%) 0.070
Concomitant coumadin
therapy on discharge
10 (17.2%) 5 (5.3%) 0.017
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Safety and Efficacy of Ultrasound-guided Thrombin Injections at the ‘Neck’ of
Pseudoaneurysms
Salem Badr, Hironori Kitabata, Israel Barbash, Saar minha, Lakshmana Pendyala,
Jousha Loh, Rebecca Torguson, Fang Chen, William Suddath, Lowell Satler,
Augusto Pichard, Ron Waksman, Nelson Bernardo
MedStar Washington Hospital Center, Washington, DC
Background: Thrombin injection has been the treatment of choice for iatrogenic arterial
pseudoaneurysms (PSAs). However, certain morphological features of the PSA, i.e. neck
width and length, occasionally precludes the use of this treatment option using the current
recommended technique.
Methods: Between March 2008 and June 2012, 146 consecutive patients who underwent
thrombin injection for post percutaneous coronary intervention related PSAs were
retrospectively studied. The technique of injecting as superficial and as far from the PSA
tract is compared with injecting at the ‘neck’ of the PSA.
Results (Table) Ninety-one patients had superficial thrombin injection (STI) and 55
patients had neck thrombin injection (NTI). Baseline characteristics were similar in both
groups. At the time of injection, all patients were on dual antiplatelet therapy and 9.6%
were on oral anti-coagulation therapy without significant difference between both groups.
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